Statins: is it really time to reassess benefits and risks?

N Engl J Med. 2012 May 10;366(19):1752-5. doi: 10.1056/NEJMp1203020. Epub 2012 Apr 25.

Author

Allison B Goldfine¹

Affiliation

¹ Harvard Medical School and the Section of Clinical, Behavioral, and Outcomes Research, Joslin Diabetes Center, Boston, USA.

PMID: 22533536
DOI: 10.1056/NEJMp1203020

No abstract available

MeSH terms

Cardiovascular Diseases / prevention & control*
Diabetes Mellitus / chemically induced*
Female
Glycated Hemoglobin
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperglycemia / chemically induced
Male
Risk Assessment

Substances

Glycated Hemoglobin A
Hydroxymethylglutaryl-CoA Reductase Inhibitors